Detalles de la búsqueda
1.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
2.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34914339
3.
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.
Breast Cancer Res Treat
; 204(1): 49-59, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38060077
4.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37387213
5.
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Breast Cancer Res Treat
; 201(1): 105-115, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37310540
6.
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Curr Treat Options Oncol
; 24(9): 1103-1119, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314645
7.
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
Future Oncol
; 19(8): 559-573, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37070653
8.
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.
Genes Dev
; 29(15): 1631-48, 2015 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26227964
9.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30786188
10.
Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Breast Cancer Res Treat
; 192(3): 509-516, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35084624
11.
Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
Breast Cancer Res Treat
; 196(3): 549-563, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36198984
12.
Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.
Breast Cancer Res Treat
; 194(1): 35-47, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35575954
13.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 195(2): 127-139, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35545724
14.
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
Breast Cancer Res
; 23(1): 16, 2021 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33517909
15.
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
Breast Cancer Res Treat
; 189(1): 1-13, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34213658
16.
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
Breast Cancer Res Treat
; 188(2): 427-432, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33837871
17.
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Breast Cancer Res Treat
; 189(1): 297-304, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34213660
18.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Breast Cancer Res Treat
; 189(1): 177-185, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34169393
19.
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
Cancer Invest
; 39(6-7): 466-472, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34075851
20.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
J Natl Compr Canc Netw
; : 1-8, 2021 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761455